Palbociclib: 13 agencies, 2017–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer -in combination…”, while PBAC (Australia) recorded not recommended for “Hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer”.
Assessment has run over 8.8 years, from 3 Feb 2017 at AWMSG (Wales) to 12 Dec 2025 at AOTMIT (Poland).
PBAC (Australia) changed its position: not recommended in 2017, recommended by 2022, after a resubmission.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 2 of 29 records date from 2023 or later.
5 distinct indication wordings are recorded for palbociclib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
5 of these 29 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess palbociclib, on 3 Feb 2017; AOTMIT (Poland) did not open a file until 12 Dec 2025 — an unusually long tail of 8.8 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 12 of 29 dated records fall in 2017 alone.
Restriction is doing real work here: 6 of 23 decisive outcomes narrowed palbociclib to a subgroup rather than accepting or refusing it outright, at AIFA (Italy), AOTMIT (Poland) and NICE (England) among others.
10 of the 13 agencies here assessed palbociclib more than once, PBAC (Australia) most often at 5 entries — repeat review is the norm for this molecule rather than the exception.
palbociclib has been through 13 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for palbociclib reads 14 recommended, 6 restricted, 4 no benefit and 3 not recommended, with 2 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 18 Oct 2023 | Re-assessment of SMR and ASMR | SMR substantial · ASMR V | source |
| G-BA (Germany) | 15 Dec 2022 | Ibrance — benefit assessment §35a | added benefit: not proven | source |
| CONITEC (Brazil) | 7 Dec 2021 | Tratamento, em primeira linha, do câncer de mama avançado ou metastático RH+/HER2, em combinação com hormonioterapia, em… | incorporated into SUS | source |
| NICE (England) | 20 Dec 2017 | NICE TA495 | recommended (optimised) | source |
| PBAC (Australia) | 2017 | Hormone receptor positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer | The PBAC did not recommend the listing of palbociclib on the PBS as initial endocrine-base… | source |
24 further decisions for palbociclib, across 13 agencies, are not shown here. They include the most recent record on file, 12 Dec 2025 from AOTMIT (Poland); its outcome is in the subscriber dataset. They link to 16 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 29 decisions for palbociclib from 13 agencies, 2017 to 2025. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.